Hsiang-Lin Tsai^*†, Yen-Cheng Chen^*‡, Tzu-Chieh Yin^*§¶, Wei-Chih Su^*‡, Po-Jung Chen^*,Tsung-Kun Chang^*†, Ching-Chun Li^*, Ching-Wen Huang^*†, Jaw-Yuan Wang^{*†‡#**††‡‡}

Oncology Research, Vol.29, No.1, pp. 47-61, 2021, DOI:10.3727/096504022X16451187313084

Abstract Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism plays a crucial role in the increased susceptibility and toxicity of patients to irinotecan. This retrospective, observational study compared the clinical outcomes and adverse events (AEs) in RAS wild-type metastatic colorectal cancer (mCRC) patients treated with cetuximab or bevacizumab plus FOLFIRI with UGT1A1 genotyping and irinotecan dose escalation as the first-line therapy. In total, 173 patients with mCRC with RAS wild-type were enrolled. Among them, 98 patients were treated with cetuximab, whereas 75 patients were treated with bevacizumab. All patients received irinotecan dose escalation based on UGT1A1 genotyping. We compared the progression-free… More >

Shuai Liu^*†1, Lu Lu^*†1, Feng Pan^‡, Chunsheng Yang^*†, Jing Liang^§, Jinfeng Liu^¶, Jian Wang^#, Rong Shen^**, Fu-Ze Xin^††, Nan Zhang^*†

Oncology Research, Vol.29, No.1, pp. 25-31, 2021, DOI:10.3727/096504022X16427607626672

Abstract Fruquintinib, also called HMPL-013, was first discovered by Hutchison Whampoa Pharmaceuticals Co. Ltd., Shanghai, China, and it is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor. In clinical trials, fruquintinib has demonstrated a survival benefit in metastatic colorectal cancer (mCRC) patients. The purpose of this study was to retrospectively evaluate the efficacy and toxicity of fruquintinib in real-world patients. We collected data from patients with mCRC treated with oral fruquintinib from 2018 to 2020 in six different institutions. Patients with mCRC initially received 5 mg of oral fruquintinib daily for 3 weeks. Progression-free survival… More >

Cheng-Jen Ma^*†‡, Ching-Wen Huang^*‡§, Yung-Sung Yeh^*†¶, Hsiang-Lin Tsai^*§#**, Huang-Ming Hu^††‡‡, I-Chen Wu^††‡‡, Tian-Lu Cheng^§§¶¶, Jaw-Yuan Wang^{*†‡§**¶¶}

Oncology Research, Vol.25, No.5, pp. 673-679, 2017, DOI:10.3727/97818823455816X14786040691928

Abstract We analyzed the results of previously treated patients with metastatic colorectal cancer (mCRC) who received regorafenib plus FOLFIRI with the irinotecan dose escalation on the basis of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping. Thirteen patients with previously treated mCRC were subjected to UGT1A1 genotyping between October 2013 and June 2015 and were administered regorafenib plus FOLFIRI with irinotecan dose escalation. Patients with UGT1A1*1/*1 and *1/*28 genotypes were administered 180 mg/m² of irinotecan, whereas those with the UGT1A1*28/*28 genotype were administered 120 mg/m2 of irinotecan. For all patients, the irinotecan dose was increased by 30 mg/m2 every… More >